LivaNova Shares Move Higher On Street-Beating Q3 Earnings

  • LivaNova PLC LIVN posted Q3 sales of $253.2 million, +5.5% Y/Y on a reported basis and 5% on a constant-currency basis, beating the consensus of $245.27 million.
  • Excluding Heart Valves business, divested in June, sales increased by 15.7% on a reported basis and 15.2% on a constant currency.
  • Sales in Cardiopulmonary products were $123.2 million, +14.5% primarily related to growth in oxygenator and heart-lung machine sales.
  • Neuromodulation sales were $113.3 million, up 14.6%, reflecting improved market dynamics across all regions.
  • Q3 adjusted EPS reached $0.68 up from $0.38 posted a year ago, easily surpassing the consensus of $0.44.
  • “Our third-quarter performance demonstrates a continued focus on execution across all regions in our key product lines amidst lingering COVID-19-related headwinds,” said CEO Damien McDonald.
  • Guidance: LivaNova raised its FY21 guidance and said it expects sales growth of 8% - 11%, compared to earlier guidance of 5% - 10%.
  • The Company expects adjusted EPS of $2.00 - $2.10, higher than prior guidance of $1.60 - $1.90.
  • Price Action: LIVN shares are up 14% at $89.16 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!